Prevention-effective adherence trajectories among transgender women indicated for PrEP in the United States: a prospective cohort study.


Journal

Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013

Informations de publication

Date de publication:
06 2022
Historique:
received: 02 11 2021
revised: 18 03 2022
accepted: 30 03 2022
pubmed: 11 4 2022
medline: 7 6 2022
entrez: 10 4 2022
Statut: ppublish

Résumé

Adherence to pre-exposure prophylaxis (PrEP) during periods of PrEP-indication (i.e., prevention-effective adherence) is critical for preventing HIV. We sought to describe factors associated with prevention-effective adherence trajectories among transgender women (TW) to inform PrEP implementation strategies. Using data from The LITE American Cohort (n = 728), we performed group-based multi-trajectory modeling (GBMTM) to identify clusters of TW with similar trajectories of PrEP adherence and indication, and sociodemographic, biobehavioral, and structural correlates of each trajectory. We identified five trajectories: (1) consistent indication/no PrEP (15.3%), (2) initial indication/no PrEP (47.1%), (3) declining indication/discontinued PrEP (9.5%), (4) consistent indication/PrEP adherent (18.5%), and (5) increasing indication/initiated PrEP (9.6%). TW diagnosed with an STI were more likely to follow a consistent indication/no PrEP trajectory compared to consistent indication/PrEP adherent trajectory (adjusted Relative Risk Ratio [aRRR], 2.54; 95% confidence interval [CI], 1.16-5.57). TW who experienced homelessness were more likely to follow PrEP discontinuation and initiation trajectories relative to PrEP adherence (aRRR, 2.71; 95% CI, 1.10-6.70 and 2.83; 95% CI, 1.13-7.05, respectively). Over a quarter of TW followed trajectories suggestive of prevention-effective adherence, while 15% did not initiate PrEP despite consistent indication. Findings highlight missed opportunities for PrEP engagement at STI diagnosis and suggest structural interventions addressing housing instability may improve prevention-effective adherence among TW.

Identifiants

pubmed: 35398255
pii: S1047-2797(22)00050-3
doi: 10.1016/j.annepidem.2022.03.016
pmc: PMC9167788
mid: NIHMS1796200
pii:
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-31

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIAID NIH HHS
ID : UG3 AI133669
Pays : United States
Organisme : NIAID NIH HHS
ID : UH3 AI133669
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH067127
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI117970
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI073961
Pays : United States
Organisme : NIMH NIH HHS
ID : F31 MH124582
Pays : United States
Organisme : NICHD NIH HHS
ID : P2C HD050924
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH114715
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Références

Prev Sci. 2017 Jul;18(5):505-516
pubmed: 28101813
Epidemiol Rev. 2018 Jun 1;40(1):27-39
pubmed: 29554240
Lancet HIV. 2018 Mar;5(3):e136-e145
pubmed: 29467098
JMIR Res Protoc. 2019 Oct 3;8(10):e14704
pubmed: 31584005
Soc Sci Med. 2019 Apr;226:225-235
pubmed: 30674436
J Community Health. 2019 Dec;44(6):1193-1203
pubmed: 31317438
AIDS. 2021 Mar 1;35(3):524-526
pubmed: 33507011
AIDS Behav. 2017 Dec;21(12):3312-3327
pubmed: 29138982
PLoS One. 2021 Jan 19;16(1):e0244226
pubmed: 33465090
Lancet Infect Dis. 2013 Mar;13(3):214-22
pubmed: 23260128
Glob Public Health. 2016 Aug-Sep;11(7-8):1060-75
pubmed: 26963756
J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21105
pubmed: 27760683
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):131-140
pubmed: 31180995
J Acquir Immune Defic Syndr. 2021 May 1;87(1):639-643
pubmed: 33512848
Soc Sci Med. 2019 Jun;230:280-294
pubmed: 31035207
J Int AIDS Soc. 2020 Jun;23 Suppl 3:e25539
pubmed: 32602642
Curr HIV/AIDS Rep. 2017 Aug;14(4):141-152
pubmed: 28752285
AIDS Behav. 2017 May;21(5):1236-1246
pubmed: 28108878
Ann Epidemiol. 2021 Dec;64:102-110
pubmed: 34563567
LGBT Health. 2018 Oct;5(7):387-390
pubmed: 30272493
JMIR Res Protoc. 2021 Apr 26;10(4):e29152
pubmed: 33900202
Stat Methods Med Res. 2018 Jul;27(7):2015-2023
pubmed: 29846144
AIDS Care. 2020 May;32(5):585-593
pubmed: 31482726
AIDS Behav. 2018 Nov;22(11):3673-3680
pubmed: 29754268
AIDS. 2015 Jul 17;29(11):1277-85
pubmed: 26103095
Arch Sex Behav. 2021 Jan;50(1):1-6
pubmed: 33507424
Lancet HIV. 2015 Dec;2(12):e512-9
pubmed: 26614965

Auteurs

Erin E Cooney (EE)

Johns Hopkins Bloomberg School of Public Health, Department of International Health, Baltimore, MD. Electronic address: Ecooney2@jhmi.edu.

Sari L Reisner (SL)

Fenway Health, The Fenway Institute, Boston, MA; Brigham and Women's Hospital, Division of Endocrinology, Diabetes, and Hypertension, Boston, MA; Harvard Medical School, Department of Medicine, Boston, MA; Harvard TH Chan School of Public Health, Department of Epidemiology, Boston, MA.

Haneefa T Saleem (HT)

Johns Hopkins Bloomberg School of Public Health, Department of International Health, Baltimore, MD.

Keri N Althoff (KN)

Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD.

S Wilson Beckham (SW)

Johns Hopkins Bloomberg School of Public Health, Department of International Health, Baltimore, MD; Johns Hopkins Bloomberg School of Public Health, Department of Health, Behavior and Society, Baltimore, MD.

Asa Radix (A)

Callen-Lorde Community Health Center, New York, NY.

Christopher M Cannon (CM)

Whitman-Walker Institute, Washington, DC.

Jason S Schneider (JS)

Emory University, School of Medicine, Atlanta, GA.

J Sonya Haw (JS)

Emory University, School of Medicine, Atlanta, GA.

Allan E Rodriguez (AE)

University of Miami Miller School of Medicine, Division of Infectious Diseases, Department of Medicine, Miami, FL.

Andrew J Wawrzyniak (AJ)

University of Miami Miller School of Medicine, Department of Psychiatry and Behavioral Sciences, Miami, FL.

Tonia C Poteat (TC)

University of North Carolina School of Medicine, Center for Health Equity Research, Chapel Hill, NC.

Kenneth H Mayer (KH)

Fenway Health, The Fenway Institute, Boston, MA; Harvard Medical School, Department of Medicine, Boston, MA.

Chris Beyrer (C)

Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD.

Andrea L Wirtz (AL)

Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH